- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...
No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% ...
1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results